State of the Science Summit on Prostate Cancer

William K. Kelly, DO, discusses the evolving imaging techniques and emerging therapeutic approaches in prostate cancer.

Robert B. Den, MD, discusses bone-targeting agents in prostate cancer and the potential future of combinations.

Edouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, discusses clinical trials that are investigating combination approaches for patients with prostate cancer.

Veda Giri, MD, discusses the developing role of genetic testing for the screening and management of patients with prostate cancer.

Leonard G. Gomella, MD, shares his insight on this year's expected advances in the field of prostate cancer.

Mark J. Mann, MD, assistant professor, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses the differences between treatment options for patients with prostate cancer subtypes.

James Luke Godwin, MD, recaps recent advancements in frontline metastatic castration-sensitive prostate cancer and highlights emerging agents with potential in this space.

Veda Giri, MD, associate professor, Thomas Jefferson University Hospital, discusses testing for inherited prostate cancer.

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, encourages early screening for prostate cancer.

Robert B. Den, MD, associate professor of radiation oncology, Thomas Jefferson University Hospital, discusses bone-targeting agents in prostate cancer.

Mark J. Mann, MD, assistant professor, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses the future of immunotherapy in prostate cancer.